Dr. Christopher Capelli M.D. serves as Vice Chairman of the Board, Chief Scientific Officer of the Company. Dr. Capelli is a co-founder of our company and has served as our chief executive officer since August 2018, president since March 2018 and chief science officer since September 2015. From September 2014 through August 2015. Dr. Capelli was a consultant to the company. Dr. Capelli is the lead inventor of Soliton’s RAP technology. From March 2005 through August 2014, Dr. Capelli served as the vice president in the office of Technology Based Ventures at The University of Texas M. D. Anderson Cancer Center. From March 2001 through February 2005, Dr. Capelli served the director of the Office of Technology Management at the University of Pittsburgh. From 1987 through 1998, Dr. Capelli served the president and was the founder of BioInterface Technologies, Inc. which developed new a silver-based antimicrobial technology for use in wound care. Dr. Capelli is a graduate of Massachusetts Institute of Technology with a Bachelor of Science degree in Mechanical Engineering. Dr. Capelli earned his MD from the University of Wisconsin Medical School and maintains a medical license in the State of Wisconsin. Capelli's history with our company as a founder and as the creator of our technology provide him with the qualifications to serve as a director.
As the Vice Chairman of the Board a Chief Scientific Officer of Soliton, the total compensation of Christopher Capelli at Soliton is $1,111,190. There are no executives at Soliton getting paid more.
Christopher Capelli is 59, he's been the Vice Chairman of the Board a Chief Scientific Officer of Soliton since 2020. There are 1 older and 4 younger executives at Soliton. The oldest executive at Soliton, Inc. is Joe Tanner, 72, who is the Chief Operating Officer.
Christopher's mailing address filed with the SEC is C/O SOLITON, INC. 5304 ASHBROOK DRIVE, , HOUSTON, TX, 77081.
Over the last 5 years, insiders at Soliton have traded over $0 worth of Soliton stock and bought 632,904 units worth $999,992 . The most active insiders traders include Walter V Klemp, Ventures Llc Remeditex a Jonathan P. Foster. On average, Soliton executives and independent directors trade stock every 126 days with the average trade being worth of $4,763,657. The most recent stock trade was executed by Ventures Llc Remeditex on 30 June 2020, trading 120,481 units of SOLY stock currently worth $999,992.
Soliton, Inc., a medical device company, develops and commercializes products using a proprietary rapid acoustic pulse technology platform. It is developing a product for the removal of tattoos. The company was founded in 2012 and is headquartered in Houston, Texas.
Soliton executives and other stock owners filed with the SEC include: